MCID: PRS038
MIFTS: 65

Personality Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Personality Disorder

MalaCards integrated aliases for Personality Disorder:

Name: Personality Disorder 12 29 15
Personality Disorders 54 42 15 70
Character Disorder 12
Personality 17

Classifications:



External Ids:

Disease Ontology 12 DOID:1510
ICD9CM 34 301.8
SNOMED-CT 67 191770003
ICD10 32 F60 F60.9
UMLS 70 C0029707 C0031212

Summaries for Personality Disorder

MedlinePlus : 42 Personality disorders are a group of mental illnesses. They involve long-term patterns of thoughts and behaviors that are unhealthy and inflexible. The behaviors cause serious problems with relationships and work. People with personality disorders have trouble dealing with everyday stresses and problems. They often have stormy relationships with other people. The cause of personality disorders is unknown. However, genes and childhood experiences may play a role. The symptoms of each personality disorder are different. They can mild or severe. People with personality disorders may have trouble realizing that they have a problem. To them, their thoughts are normal, and they often blame others for their problems. They may try to get help because of their problems with relationships and work. Treatment usually includes talk therapy and sometimes medicine.

MalaCards based summary : Personality Disorder, also known as personality disorders, is related to dependent personality disorder and obsessive-compulsive personality disorder, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Methylene blue and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, prostate and skin, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A disease of mental health that involve long-term patterns of thoughts and behaviors that cause serious problems with relationships and work.

Wikipedia : 73 Personality disorders (PD) are a class of mental disorders characterized by enduring maladaptive... more...

Related Diseases for Personality Disorder

Diseases in the Personality Disorder family:

Multiple Personality Disorder

Diseases related to Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 926)
# Related Disease Score Top Affiliating Genes
1 dependent personality disorder 33.1 MAOA DRD4
2 obsessive-compulsive personality disorder 33.0 SLC6A4 HTR2A DRD3 COMT
3 intermittent explosive disorder 32.2 SLC6A4 MAOA HTR2C HTR2A HTR1A COMT
4 cyclothymic disorder 32.0 SLC6A4 HTR2C HTR2A DRD4 DRD2 COMT
5 antisocial personality disorder 32.0 SLC6A4 SLC6A3 PRL OXTR MAOB MAOA
6 barbiturate dependence 31.7 TPH1 SLC6A4
7 conduct disorder 31.4 TPH1 SLC6A4 SLC6A3 OXTR MAOA DRD4
8 borderline personality disorder 31.2 TPH2 TPH1 SLC6A4 SLC6A3 PRL OXTR
9 dissociative disorder 31.1 SLC6A4 FKBP5 BDNF
10 alexithymia 31.1 SLC6A4 OXTR HTR1A DRD2 COMT
11 somatization disorder 31.0 SLC6A4 HTR1A CRH COMT
12 acute stress disorder 30.9 SLC6A4 NR3C1 HTR1A FKBP5 CRH BDNF
13 pyromania 30.8 MAOA HTR1B
14 pedophilia 30.8 PRL MAOA
15 neurotic disorder 30.8 SLC6A4 MAOA HTR2A HTR1A COMT BDNF
16 traumatic brain injury 30.8 DRD2 COMT BDNF
17 brain injury 30.8 DRD2 COMT BDNF
18 body dysmorphic disorder 30.7 SLC6A4 MAOA HTR2A
19 social phobia 30.7 SLC6A4 PRL MAOA HTR2A HTR1A DRD2
20 agoraphobia 30.7 SLC6A4 MAOA HTR2A HTR1A CRH COMT
21 impulse control disorder 30.7 SLC6A4 SLC6A3 MAOB MAOA HTR2C HTR2A
22 bulimia nervosa 30.7 SLC6A4 MAOA HTR2C HTR2A HTR1B DRD4
23 hypochondriasis 30.7 SLC6A4 HTR2C HTR2A HTR1A BDNF
24 depression 30.7 TPH2 TPH1 SLC6A4 PRL NR3C1 MAOA
25 trichotillomania 30.6 PRL MAOA DRD4
26 eating disorder 30.6 SLC6A4 SLC6A3 OXTR HTR2C HTR2A DRD3
27 somatoform disorder 30.6 TPH1 SLC6A4 CRH COMT BDNF
28 drug dependence 30.6 SLC6A4 SLC6A3 DRD3 DRD2 CRH BDNF
29 sexual sadism 30.5 PRL MAOA CRH COMT BDNF
30 polysubstance abuse 30.5 DRD3 DRD2 COMT
31 exhibitionism 30.5 MAOA DRD4
32 bipolar i disorder 30.5 TPH2 SLC6A4 HTR2C HTR2A HTR1A DRD2
33 galactorrhea 30.5 PRL DRD2
34 dysthymic disorder 30.4 SLC6A4 SLC6A3 MAOA HTR2C HTR2A HTR1A
35 schizoaffective disorder 30.4 SLC6A4 PRL HTR2A HTR1A DRD3 DRD2
36 post-traumatic stress disorder 30.4 SLC6A4 OXTR NR3C1 MAOB MAOA HTR2A
37 paraphilia disorder 30.4 SLC6A4 MAOA DRD4 DRD2
38 irritable bowel syndrome 30.4 TPH1 SLC6A4 HTR2A HTR1A CRH COMT
39 substance abuse 30.4 SLC6A4 SLC6A3 PRL MAOA HTR2A HTR1B
40 fibromyalgia 30.4 SLC6A4 HTR2A CRH COMT BDNF
41 cocaine dependence 30.3 TPH2 SLC6A4 SLC6A3 HTR2A DRD3 DRD2
42 generalized anxiety disorder 30.3 TPH1 SLC6A4 SLC6A3 NR3C1 MAOA HTR2A
43 anorexia nervosa 30.3 SLC6A4 PRL MAOA HTR2C HTR2A HTR1A
44 alcohol use disorder 30.3 SLC6A4 SLC6A3 HTR2C HTR2A HTR1B HTR1A
45 sleep apnea 30.3 SLC6A4 HTR2C HTR2A BDNF
46 migraine without aura 30.2 SLC6A4 PRL HTR1A DRD4 DRD3 DRD2
47 supranuclear palsy, progressive, 1 30.2 SLC6A3 MAOB DRD2
48 sexual disorder 30.2 SLC6A4 PRL HTR2C HTR2A HTR1A BDNF
49 kleptomania 30.2 SLC6A4 MAOA HTR1A DRD2 COMT
50 paine syndrome 30.2 SLC6A4 CRH COMT BDNF

Comorbidity relations with Personality Disorder via Phenotypic Disease Network (PDN): (show all 14)


Acute Cystitis Alzheimer Disease
Anxiety Deficiency Anemia
Dependent Personality Disorder Dysthymic Disorder
Generalized Anxiety Disorder Heart Disease
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Personality Disorder:



Diseases related to Personality Disorder

Symptoms & Phenotypes for Personality Disorder

UMLS symptoms related to Personality Disorder:


photophobia; restlessness; personality changes; pseudobulbar behavioral symptoms; sleep disturbances

GenomeRNAi Phenotypes related to Personality Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.55 MAOA NR3C1
2 Decreased viability GR00240-S-1 9.55 COMT
3 Decreased viability GR00249-S 9.55 COMT MAOB SLC6A4 TPH1
4 Decreased viability GR00381-A-1 9.55 HTR1A SLC6A4
5 Decreased viability GR00381-A-3 9.55 HTR1A SLC6A4
6 Decreased viability GR00386-A-1 9.55 COMT FKBP5 TPH2
7 Decreased viability GR00402-S-2 9.55 HTR1A OXTR TPH2

MGI Mouse Phenotypes related to Personality Disorder:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.48 BDNF COMT CRH DRD2 DRD3 DRD4
2 homeostasis/metabolism MP:0005376 10.33 BDNF COMT CRH DRD2 DRD3 DRD4
3 growth/size/body region MP:0005378 10.25 BDNF CRH DRD2 DRD3 FKBP5 HTR1B
4 endocrine/exocrine gland MP:0005379 10.23 BDNF COMT CRH DRD2 HTR1B HTR2A
5 nervous system MP:0003631 10.19 BDNF COMT CRH DRD2 DRD3 DRD4
6 adipose tissue MP:0005375 10.15 CRH DRD2 DRD3 HTR1A HTR1B HTR2C
7 integument MP:0010771 10.11 BDNF CRH DRD2 HTR2C NR3C1 OXTR
8 muscle MP:0005369 9.97 DRD2 HTR1B HTR2A HTR2C NR3C1 OXTR
9 no phenotypic analysis MP:0003012 9.76 BDNF CRH DRD2 HTR1A HTR1B NR3C1
10 normal MP:0002873 9.61 BDNF CRH DRD2 FKBP5 NR3C1 OXTR
11 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Personality Disorder

Drugs for Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1002)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylene blue Approved, Investigational Phase 4 61-73-4
2
Abatacept Approved Phase 4 332348-12-6 10237
3
Roxithromycin Approved, Investigational, Withdrawn Phase 4 80214-83-1 6915744 444037
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Nicotine Approved Phase 4 54-11-5 942 89594
7
Haloperidol Approved Phase 4 52-86-8 3559
8
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
9
Cetirizine Approved Phase 4 83881-51-0 2678
10 Orange Approved Phase 4
11
Atorvastatin Approved Phase 4 134523-00-5 60823
12
Perphenazine Approved Phase 4 58-39-9 4748
13
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
14
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
15
Infliximab Approved Phase 4 170277-31-3
16
Liraglutide Approved Phase 4 204656-20-2 44147092
17
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
18
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
19
Calcium carbonate Approved, Investigational Phase 4 471-34-1
20
Zinc oxide Approved Phase 4 1314-13-2
21
Didanosine Approved Phase 4 69655-05-6 50599
22
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
23
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
24
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
25
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
26
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
27
Acyclovir Approved Phase 4 59277-89-3 2022
28
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
29
Nevirapine Approved Phase 4 129618-40-2 4463
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
31
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
32
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
33
Ledipasvir Approved Phase 4 1256388-51-8 67505836
34
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
35
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
36
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
37
Estazolam Approved, Illicit Phase 4 29975-16-4 3261
38
Flurazepam Approved, Illicit, Investigational Phase 4 17617-23-1 3393
39
Nitrazepam Approved Phase 4 146-22-5 4506
40
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
41
Licorice Approved Phase 4
42
Ibuprofen Approved Phase 4 15687-27-1 3672
43
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
44
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
45
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
46
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
47
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
48
Zidovudine Approved Phase 4 30516-87-1 35370
49
Ofloxacin Approved Phase 4 82419-36-1 4583
50
Clarithromycin Approved Phase 4 81103-11-9 84029

Interventional clinical trials:

(show top 50) (show all 6510)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD Unknown status NCT00743834 Phase 4 Luvox CR
3 Treatment With Escitalopram (Cipralex®) for Adolescents With Obsessive-Compulsive Disorder: Efficacy, Safety, and Changes in Executive Functions, Metacognition, and Regional Brain Activations. Unknown status NCT00708240 Phase 4 Escitalopram
4 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
5 Propranolol Reactivation Mismatch (PRM) Treatment for PTSD: A Pilot Study Unknown status NCT03652922 Phase 4 Reactivation Mismatch
6 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
7 Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02745132 Phase 4
8 Functional Electrical Stimulation (FES)-Assisted Walking: Enhancement of Voluntary Walking Function Among Persons With Severe Hemiplegia Post-Stroke Unknown status NCT00552916 Phase 4
9 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
10 A Pilot Study Using a Randomized Design to Evaluate the Immunologic Efficacy and Safety of ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors Unknown status NCT02444936 Phase 4 ZOSTAVAX
11 Prevention of Potentially Inappropriate Prescribing in Late Life Using STOPP (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions) and START (Screening Tool to Alert Doctors to Right i.e. Appropriate Indicated Treatment): A Randomized Controlled Trial. Unknown status NCT00915824 Phase 4
12 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
13 Personalized Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01570621 Phase 4
14 Effect of Mobile-Directly Observed Therapy (DOT) on Adherence to Hydroxyurea Treatment in Adult HbSS Patients at Muhimbili National Hospital (MNH) in Tanzania: a Pilot Study Unknown status NCT02844673 Phase 4 Hydroxyurea
15 10-Day Antimicrobial Susceptibility Testing Guided Triple Therapy Versus 14-Day Empirical Tailored Therapy for the First-line Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail Unknown status NCT03571230 Phase 4 two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline);two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone);one proton pump inhibitor(PPI);Colloidal Bismuth Pectin;two antibiotics for failed eradication(tetracyclin,furazolidone)
16 Precision Medicine Offers Belatacept Monotherapy (PROBE) Unknown status NCT02939365 Phase 4 Belatacept
17 A Randomized Controlled Study of Compound Lidocaine Cream to Prevent Postoperative Agitation in Patients With Endotracheal Intubation for General Anesthesia Unknown status NCT02017392 Phase 4 Compound Lidocaine Cream
18 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
19 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS) Completed NCT00204347 Phase 4 risperidone
20 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
21 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
22 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
23 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
24 Escitalopram for the Treatment of Obsessive Compulsive Disorder Completed NCT00116532 Phase 4 Escitalopram
25 Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
26 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
27 Multimodal Treatment Study of Children With ADHD Completed NCT00000388 Phase 4 Anti-ADHD medication
28 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
29 Duloxetine for the Treatment of Obsessive Compulsive Disorder Completed NCT00464698 Phase 4 Duloxetine
30 SSRI-Induced Activation Syndrome in Pediatric Obsessive Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
31 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
32 A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder Completed NCT00182520 Phase 4 Topiramate;placebo
33 Reclaim® Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder: Post-Market Clinical Follow-up Study (OCD PMCF) Completed NCT01135745 Phase 4
34 Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial. Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
35 An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
36 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
37 Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder Completed NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
38 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
39 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? A Randomized, Double-blind, Placebo-controlled National Study Completed NCT02656342 Phase 4 D-Cycloserine;Placebo
40 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Completed NCT00994786 Phase 4 pregabalin;Placebo
41 Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study Completed NCT00796497 Phase 4 ondansetron
42 Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
43 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder (Randomized, Double-blind, Multi-center Study) Completed NCT00723060 Phase 4 escitalopram
44 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
45 Project 2: Identifying Optimal Smoking Cessation Intervention Components Completed NCT01116986 Phase 4 Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt;Short Term Nicotine Patch + Nicotine Gum during the quit attempt;Pre-Quit Nicotine Gum;Pre-Quit Nicotine Patch;Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum
46 Project 3: Identifying Optimal Strategies of Increasing Smokers' Adherence to Cessation Medications Completed NCT01120704 Phase 4 Short Term Combination Nicotine Replacement Therapy (patch + gum);Long Term Combination Nicotine Replacement Therapy (patch + gum)
47 Hyperoxia: An Unrecognized Mechanism for Inducing "Hypoxia-Like" Symptoms Completed NCT03268590 Phase 4 Oxygen
48 Immunogenicity and Safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) for Adult Use Vaccine Compared With U.S. Manufactured Tetanus and Diphtheria Toxoids Adsorbed for Adult Use Vaccine In Persons 60 Years of Age and Older and Immunogenicity and Safety of Canadian Td Vaccine in Persons 11 Through 59 Years of Age Completed NCT00601835 Phase 4
49 Stress, Anxiety and Type A Personality and Analgesics. Impact on Induction Time and Consumption of Analgesics During Cardiac Surgery Completed NCT02756598 Phase 4 Sufentanil I;Sufentanil II;Propofol I;Propofol II
50 Delayed Sleep Phase Syndrome in Adolescents and Young Adults. Sleep, Personality, Developmental History, Circadian Rhythm, Daytime Functioning and Treatment Completed NCT00834886 Phase 4

Search NIH Clinical Center for Personality Disorder

Genetic Tests for Personality Disorder

Genetic tests related to Personality Disorder:

# Genetic test Affiliating Genes
1 Personality Disorder 29

Anatomical Context for Personality Disorder

MalaCards organs/tissues related to Personality Disorder:

40
Spinal Cord, Prostate, Skin, Breast, Bone, Cortex, Eye

Publications for Personality Disorder

Articles related to Personality Disorder:

(show top 50) (show all 20463)
# Title Authors PMID Year
1
Schema therapy with exposure and response prevention for the treatment of chronic anxiety with comorbid personality disorder. 61 42
33319395 2021
2
Pathological Narcissism, Negative Parenting Styles and Interpersonal Forgiveness among Psychiatric Outpatients. 42
33370738 2020
3
Coupling of autism genes to tissue-wide expression and dysfunction of synapse, calcium signalling and transcriptional regulation. 42
33338084 2020
4
A gene-environment investigation on personality traits in two independent clinical sets of adult patients with personality disorder and attention deficit/hyperactive disorder. 61 54
19894072 2010
5
Fluoxetine response in impulsive-aggressive behavior and serotonin transporter polymorphism in personality disorder. 61 54
20010449 2010
6
Detecting psychopathy from thin slices of behavior. 54 61
19290767 2009
7
Tryptophan hydroxylase-2 gene variation influences personality traits and disorders related to emotional dysregulation. 54 61
17176492 2007
8
Preliminary evidence for an association between a dopamine D3 receptor gene variant and obsessive-compulsive personality disorder in patients with major depression. 54 61
16583407 2006
9
Cluster B personality disorders are associated with allelic variation of monoamine oxidase A activity. 54 61
15870836 2005
10
The childhood-onset neuropsychiatric background to adulthood psychopathic traits and personality disorders. 61 54
15723027 2005
11
Association between allelic variation of serotonin transporter function and neuroticism in anxious cluster C personality disorders. 54 61
14992987 2004
12
Dimensions of personality disorders in offenders. 54 61
15614323 2004
13
Polymorphisms of DRD4 and DRD3 and risk of avoidant and obsessive personality traits and disorders. 61 54
12860355 2003
14
Mild learning difficulties and offending behaviour--is there a link with monoamine oxidase A deficiency? 54 61
11702062 2001
15
Polymorphism in exon 6 of the dopamine D(2) receptor gene (DRD2) is associated with elevated blood pressure and personality disorders in men. 61 54
11494094 2001
16
Suicide, impulsive aggression, and HTR1B genotype. 61 54
11457425 2001
17
Cluster C personality disorder has no independent effect on striatal dopamine transporter densities in major depression. 61 54
11374331 2001
18
Serotonin transporter protein gene polymorphism and personality measures in African American and European American subjects. 61 54
9766763 1998
19
Tryptophan hydroxylase genotype is associated with impulsive-aggression measures: a preliminary study. 61 54
9514581 1998
20
Differential psychopathological profile of male intimate partner violence perpetrators depending on Problematic alcohol use. 61
33714033 2021
21
Emotional working memory updating in individuals with borderline personality features. 61
33476888 2021
22
Childhood trauma determines different clinical and biological manifestations in patients with eating disorders. 61
32424563 2021
23
Changing Outdated Methadone Regulations That Harm Pregnant Patients. 61
32826620 2021
24
Avoidable emergency department presentations for dental comorbidities of psychiatric disorders: A population-based record-linkage analysis. 61
33611073 2021
25
An empirically derived hierarchical tree typology of DSM-5 pathological personality traits in adolescence. 61
33793266 2021
26
Criterion A Scales: Convergent, Discriminant, and Structural Relationships. 61
32749149 2021
27
A mixed methods study of the healthcare received by patients diagnosed with a personality disorder on acute general hospital wards. 61
33594716 2021
28
A Case of Self-Cannibalism: An Extremely Rare Type of Self-Mutilation With Multiple Risk Factors. 61
33764950 2021
29
Unraveling the Personality Profile of the Sexual Murderer. 61
29783916 2021
30
Linking experiences of child sexual abuse to adult sexual intimate partner violence: the role of borderline personality features, maladaptive cognitive emotion regulation, and dissociation. 61
33789778 2021
31
The Course of Borderline Psychopathology in Adolescents with Complex Mental Health Problems: An 18 Month Longitudinal Follow-up Study. 61
33439418 2021
32
Differential diagnosis of borderline personality disorder and bipolar disorder: self-concept, identity and self-esteem. 61
33811707 2021
33
Emotional and Behavioral Dysregulation in Severe Mental Illness. 61
33743948 2021
34
Current rodent models for the study of empathic processes. 61
33136617 2021
35
Alternative DSM-5 Model for Personality Disorders Through the Lens of an Empirical Network Model. 61
31928067 2021
36
Personality Disorders in the ICD-11: Spanish Validation of the PiCD and the SASPD in a Mixed Community and Clinical Sample. 61
32583685 2021
37
A Plea for Preregistration in Personality Disorders Research: The Case of Psychopathy. 61
30920938 2021
38
Screening for Borderline Personality Disorder With the McLean Screening Instrument: A Review and Critique of the Literature. 61
31887102 2021
39
Interpersonal Problems in Borderline Personality Disorder: Associations With Mentalizing, Emotion Regulation, and Impulsiveness. 61
30920937 2021
40
Effect of Psychotherapy for Borderline Personality Disorder on Quality of Life: A Systematic Review and Meta-Analysis. 61
31609187 2021
41
Perspectives of crisis intervention for people diagnosed with "borderline personality disorder": An integrative review. 61
32367638 2021
42
Is There a Bias in the Diagnosis of Borderline Personality Disorder Among Lesbian, Gay, and Bisexual Patients? 61
32981328 2021
43
The case for cautious paternalism in the emergency management of patients with borderline personality disorder. 61
33478605 2021
44
Presentation of Borderline Personality Disorder Symptoms in Adulthood: Development of Depression Mediates the Effect of Childhood and Adolescent Exposure to Violence. 61
33346599 2021
45
Borderline Personality Disorder Features and Risk for Prescription Opioid Misuse in a Chronic Pain Sample: Roles for Identity Disturbances and Impulsivity. 61
31609188 2021
46
Facial Emotion Perception in Borderline Personality Disorder: Differential Neural Activation to Ambiguous and Threatening Expressions and Links to Impairments in Self and Interpersonal Functioning. 61
33592431 2021
47
Effectiveness of brief schema group therapy for borderline personality disorder symptoms: a randomized pilot study. 61
33103925 2021
48
Personality, Schizophrenia, and Violence: A Longitudinal Study: The Second Wave of the VIORMED Project. 61
31609185 2021
49
Use of methylphenidate and the incidence of intentional self-harm or suicide attempts among individuals with schizophrenia, bipolar disorder and personality disorder. 61
33636995 2021
50
Substance use among patients in specialized mental health services in Norway: prevalence and patient characteristics based on a national census. 61
32945698 2021

Variations for Personality Disorder

Expression for Personality Disorder

Search GEO for disease gene expression data for Personality Disorder.

Pathways for Personality Disorder

Pathways related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 PRL OXTR NR3C1 HTR2C HTR2A HTR1B
2
Show member pathways
12.71 SLC6A3 MAOB MAOA DRD4 DRD3 DRD2
3 12.29 OXTR HTR1B HTR1A DRD2 BDNF
5 12.07 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2A
6
Show member pathways
11.93 SLC6A3 MAOB MAOA DRD2 BDNF
7
Show member pathways
11.91 HTR2C HTR2A HTR1B HTR1A DRD4 DRD3
8 11.87 TPH2 TPH1 SLC6A4 MAOB MAOA HTR2C
9
Show member pathways
11.84 TPH2 TPH1 MAOB MAOA
10 11.8 HTR2A DRD4 DRD3
11
Show member pathways
11.79 DRD4 DRD3 DRD2
12
Show member pathways
11.78 TPH2 TPH1 MAOB MAOA
13 11.72 HTR2C HTR2A DRD2
14 11.68 PRL NR3C1 FKBP5
15
Show member pathways
11.66 MAOB MAOA COMT
16
Show member pathways
11.41 TPH2 SLC6A4 SLC6A3 MAOA
17
Show member pathways
11.12 SLC6A4 SLC6A3 MAOA COMT
18
Show member pathways
11.09 TPH1 MAOA COMT
19 11.01 PRL HTR2C DRD2
20 11 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
21
Show member pathways
10.88 MAOB MAOA COMT
22 10.83 MAOB MAOA COMT
23
Show member pathways
10.73 TPH2 SLC6A4 SLC6A3 MAOB MAOA HTR1B
24
Show member pathways
10.72 MAOB MAOA

GO Terms for Personality Disorder

Cellular components related to Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.29 SLC6A4 SLC6A3 OXTR MAOB MAOA HTR2C
2 integral component of plasma membrane GO:0005887 9.96 SLC6A4 SLC6A3 OXTR HTR2C HTR2A HTR1B
3 synapse GO:0045202 9.95 SLC6A4 HTR2C HTR2A HTR1A DRD3 DRD2
4 axon GO:0030424 9.83 SLC6A3 HTR2A DRD2 COMT BDNF
5 integral component of postsynaptic membrane GO:0099055 9.62 SLC6A4 SLC6A3 HTR2A DRD2
6 dendrite GO:0030425 9.56 HTR2C HTR2A HTR1B HTR1A DRD4 DRD2
7 dopaminergic synapse GO:0098691 9.46 SLC6A3 DRD2
8 serotonergic synapse GO:0099154 9.37 SLC6A4 HTR1B
9 G protein-coupled serotonin receptor complex GO:0098666 9.33 HTR2C HTR2A HTR1B
10 integral component of presynaptic membrane GO:0099056 9.02 SLC6A4 SLC6A3 HTR2A HTR1B DRD2

Biological processes related to Personality Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.3 PRL OXTR NR3C1 HTR2C HTR2A HTR1B
2 G protein-coupled receptor signaling pathway GO:0007186 10.26 OXTR HTR2C HTR2A HTR1B HTR1A DRD4
3 positive regulation of cell proliferation GO:0008284 10.14 PRL HTR2A HTR1A DRD3 CRH
4 chemical synaptic transmission GO:0007268 10.04 HTR2C HTR2A HTR1B HTR1A DRD4 CRH
5 cellular calcium ion homeostasis GO:0006874 9.96 HTR2C HTR2A DRD4 DRD3 DRD2
6 female pregnancy GO:0007565 9.94 PRL OXTR CRH COMT
7 locomotory behavior GO:0007626 9.93 SLC6A3 HTR2C DRD3 DRD2
8 memory GO:0007613 9.93 SLC6A4 OXTR HTR2A BDNF
9 response to toxic substance GO:0009636 9.91 SLC6A4 MAOB DRD2
10 circadian rhythm GO:0007623 9.91 TPH2 TPH1 SLC6A4
11 response to ethanol GO:0045471 9.91 SLC6A3 MAOB HTR1B DRD3 DRD2 CRH
12 response to estrogen GO:0043627 9.89 TPH2 CRH COMT
13 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.89 HTR2C HTR2A HTR1B HTR1A DRD4
14 positive regulation of fat cell differentiation GO:0045600 9.88 TPH1 HTR2C HTR2A
15 social behavior GO:0035176 9.88 SLC6A4 OXTR DRD4 DRD3
16 regulation of synaptic vesicle exocytosis GO:2000300 9.87 HTR2A HTR1B DRD2
17 lactation GO:0007595 9.87 SLC6A3 PRL OXTR
18 release of sequestered calcium ion into cytosol GO:0051209 9.86 HTR2C HTR2A DRD2
19 feeding behavior GO:0007631 9.84 HTR2C HTR1B DRD2
20 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.84 HTR2C DRD3 DRD2
21 regulation of dopamine secretion GO:0014059 9.84 HTR2A HTR1B DRD3 DRD2
22 response to amphetamine GO:0001975 9.83 OXTR DRD4 DRD2
23 behavioral fear response GO:0001662 9.83 HTR2C HTR1A DRD4
24 arachidonic acid secretion GO:0050482 9.82 DRD4 DRD3 DRD2
25 negative regulation of protein secretion GO:0050709 9.82 DRD4 DRD3 DRD2
26 vasoconstriction GO:0042310 9.8 SLC6A4 HTR1B HTR1A
27 G protein-coupled receptor internalization GO:0002031 9.79 HTR1B DRD3 DRD2
28 prepulse inhibition GO:0060134 9.79 SLC6A3 DRD3 DRD2
29 dopamine metabolic process GO:0042417 9.78 DRD4 DRD3 DRD2 COMT
30 neurotransmitter catabolic process GO:0042135 9.77 MAOB MAOA COMT
31 negative regulation of voltage-gated calcium channel activity GO:1901386 9.77 DRD4 DRD3 DRD2
32 behavior GO:0007610 9.76 HTR2C HTR2A HTR1B HTR1A
33 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.75 DRD3 DRD2
34 response to pain GO:0048265 9.75 CRH COMT
35 bone remodeling GO:0046849 9.75 TPH1 HTR1B
36 regulation of dopamine metabolic process GO:0042053 9.75 SLC6A3 HTR1A DRD4
37 response to iron ion GO:0010039 9.74 SLC6A3 DRD2
38 negative regulation of cytosolic calcium ion concentration GO:0051481 9.74 DRD3 DRD2
39 neurotransmitter biosynthetic process GO:0042136 9.74 SLC6A4 SLC6A3
40 positive regulation of renal sodium excretion GO:0035815 9.74 DRD3 DRD2
41 catecholamine metabolic process GO:0006584 9.74 MAOA COMT
42 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.73 DRD4 DRD3
43 sleep GO:0030431 9.73 OXTR HTR2A
44 regulation of behavior GO:0050795 9.73 HTR1B HTR1A
45 monoamine transport GO:0015844 9.73 SLC6A4 SLC6A3
46 aromatic amino acid family metabolic process GO:0009072 9.73 TPH2 TPH1
47 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.72 DRD3 DRD2
48 behavioral response to ethanol GO:0048149 9.72 DRD4 DRD2
49 adenohypophysis development GO:0021984 9.72 SLC6A3 DRD2
50 hyaloid vascular plexus regression GO:1990384 9.72 SLC6A3 DRD2

Molecular functions related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 10.01 OXTR HTR2C HTR2A HTR1B HTR1A DRD4
2 neurotransmitter receptor activity GO:0030594 9.65 HTR2C HTR2A HTR1B HTR1A DRD4
3 neurotransmitter transporter activity GO:0005326 9.54 SLC6A4 SLC6A3
4 dopamine binding GO:0035240 9.54 SLC6A3 DRD4 DRD2
5 monoamine transmembrane transporter activity GO:0008504 9.52 SLC6A4 SLC6A3
6 primary amine oxidase activity GO:0008131 9.51 MAOB MAOA
7 dopamine neurotransmitter receptor activity GO:0004952 9.5 DRD4 DRD3 DRD2
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.49 TPH2 TPH1
9 Gq/11-coupled serotonin receptor activity GO:0001587 9.48 HTR2C HTR2A
10 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.46 HTR2C HTR2A
11 tryptophan 5-monooxygenase activity GO:0004510 9.43 TPH2 TPH1
12 G protein-coupled serotonin receptor activity GO:0004993 9.35 HTR2C HTR2A HTR1B HTR1A DRD4
13 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.33 DRD4 DRD3 DRD2
14 serotonin binding GO:0051378 9.02 SLC6A4 HTR2C HTR2A HTR1B HTR1A

Sources for Personality Disorder

1